WASHINGTON — Chinese investors have been pouring money into U.S. biotech companies. That’s why the Trump administration’s new rules issued last month putting certain foreign investments under greater scrutiny came as a worrisome development for many in the industry.

The new rules are complicated, and there’s a lot of uncertainty about how they’ll be enforced — as well as, crucially, whether they’ll slow the flow of capital from China into the U.S. biotech sector. We called up lawyers to help map out what you need to know before the first stage of the regulation goes into effect next week.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy